Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 4/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | F2R | P25116 | 1/20 | 0.51 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.49 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211340 | 0.82 | KCNK3 (0.72) | KCNK3KCNK9RXFP1F2RAVPR2 | |
| SCHEMBL4753755 | 0.82 | KCNK3 (0.72) | KCNK3KCNK9RXFP1F2RAVPR2 | |
| SCHEMBL14372361 | 0.81 | KCNK3 (0.67) | KCNK3KCNK9RXFP1F2R | |
| SCHEMBL7027818 | 0.79 | CA1 (0.50) | KCNK3KCNK9RXFP1F2RKDM4E | |
| SCHEMBL7025649 | 0.76 | KCNK3 (0.44) | KCNK3KCNK9RXFP1F2R | |
| SCHEMBL22819921 | 0.76 | RXFP1 (0.61) | KCNK3KCNK9RXFP1F2RBRAF | |
| SCHEMBL1197921 | 0.74 | KCNK3 (0.73) | KCNK3KCNK9RXFP1F2RP2RX1 | |
| SCHEMBL7028191 | 0.73 | TSHR (0.46) | F2RKMT2AKDM4ELMNAHSD17B10 | |
| SCHEMBL29211148 | 0.73 | AVPR2 (0.64) | KCNK3KCNK9RXFP1F2RAVPR2 | |
| Hydrochloric Acid SCHEMBL2105897 | 0.72 | KCNK3 (0.70) | KCNK3KCNK9RXFP1F2RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2020-09-10 | — | — | US | disclosed |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-09-05 | — | — | US | disclosed |
| US-10329275-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180291000-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-2611777-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL]AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | KCNK3 1956/4885KCNK9 1726/4885RXFP1 1574/4885 |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | KCNK3 1384/4885KCNK9 1263/4885RXFP1 1095/4885 |
| US-20180291000-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | KCNK3 1384/4885KCNK9 1263/4885RXFP1 1095/4885 |
| US-10329275-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | KCNK3 1956/4885KCNK9 1726/4885RXFP1 1574/4885 |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | KCNK3 1384/4885KCNK9 1263/4885RXFP1 1095/4885 |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KCNK3 2126/4885KCNK9 1888/4885RXFP1 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.